Diabetes Research and Clinical Practice
Volume 72, Issue 3 , Pages 231-237 , June 2006

Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD

  • Signorelli Salvatore Santo

      Affiliations

    • Department of Internal Medicine and Systemic Pathology, Medical Angiology Section, Italy
    • Corresponding Author InformationCorresponding author at: Department of Internal Medicine and Systemic Pathology, Medical Angiology Section, Via Firenze 123, I-95020 Acicastello, Italy. Tel.: +39 095 7594344; fax: +39 095 312165.
    • ,
  • Neri Sergio

      Affiliations

    • Department of Internal Medicine and Systemic Pathology, Internal Medicine Section, Italy
    • ,
  • Di Pino Luigi

      Affiliations

    • Department of Internal Medicine and Systemic Pathology, Medical Angiology Section, Italy
    • ,
  • Marchese Giuseppe

      Affiliations

    • Department of Internal Medicine and Systemic Pathology, Medical Angiology Section, Italy
    • ,
  • Ferrante Margherita

      Affiliations

    • Department of Anatomy, Diagnostic Pathology, Legal Medicine and Public Health, Faculty of Medicine, University of Catania, Italy
    • ,
  • Oliveri Conti Gea

      Affiliations

    • Department of Anatomy, Diagnostic Pathology, Legal Medicine and Public Health, Faculty of Medicine, University of Catania, Italy
    • ,
  • Fallico Roberto

      Affiliations

    • Department of Anatomy, Diagnostic Pathology, Legal Medicine and Public Health, Faculty of Medicine, University of Catania, Italy
    • ,
  • Celotta Gabriella

      Affiliations

    • Department of Internal Medicine and Systemic Pathology, Medical Angiology Section, Italy
    • ,
  • Pennisi Giuseppe

      Affiliations

    • Department of Internal Medicine and Systemic Pathology, Medical Angiology Section, Italy
    • ,
  • Anzaldi Massimiliano

      Affiliations

    • Department of Internal Medicine and Systemic Pathology, Medical Angiology Section, Italy

Received 11 April 2005 ,Revised 30 August 2005 ,Accepted 14 October 2005.

References 

  1. Beach KW, Strandness DE. Arteriosclerosis obliterans and associated risk factors in insulin-dependent and non-insulin-dependent diabetes. Diabetes. 1980;29:882–888
  2. Brand FN, Abbott RD, Kannel WB. Diabetes, intermittent claudication, and risk of cardiovascular events. The Framingham Study. Diabetes. 1989;38:504–509
  3. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc. Diabetol. 2002;1:1
  4. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab. 2001;27:535–542
  5. Tooke JE. Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes. J. Diabetes Complications. 2000;14:197–200
  6. Steiner G. The diabetes atherosclerosis intervention study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group. Diabetologia. 1996;39:1655–1661
  7. Hiatt WR. Current and future drug therapies for claudication. Vasc. Med. 1997;2(3):257–262
  8. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy. Diabetes Care. 2003;26(5):1589–1596
  9. Evans AM, Fornasini G. Pharmacokinetics of l-carnitine. Clin. Pharmacokinet. 2003;42(11):941–967
  10. Brass EP, Hoppel CL. Relationship between acid-soluble carnitine and coenzyme A pools in vivo. Biochem. J. 1980;190(3):495–504
  11. Cittanti C, Colamussi P, Giganti M, Orlandi C, Uccelli L, Manfrini S, et al. Technetium-99m sestamibi leg scintigraphy for non-invasive assessment of propionyl-l-carnitine induced changes in skeletal muscle metabolism. Eur. J. Nucl. Med. 1997;24(7):762–766
  12. Ferrari R, Ceconi C, Cargnoni A, et al. The effect of propionyl-l-carnitine on the ischemic and reperfused intact myocardium and on their derived mitochondria. Cardiovasc. Drugs Ther. 1991;5(Suppl. 1):57–65
  13. Reznick AZ, Kagan VE, Ramsey R, Tsuchiya M, Khwaja S, Serbinova EA, et al. Antiradical effects in l-propionyl-carnitine protection of the heart against ischemia-reperfusion injury: the possible role of iron chelation. Arch. Biochem. Biophys. 1992;296(2):394–401
  14. Di Lisa F, Menabo R, Siliprandi N. l-Propionyl-carnitine protection of mitochondria in ischemic rat hearts. Mol. Cell Biochem. 1989;88(1/2):169–173
  15. Brevetti G, Perna S, Sabba C, Rossini A, Scotto di Uccio V, et al. Superiority of l-propionyl carnitine vs l-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur. Heart J. 1992;13(2):251–255
  16. Sabba C, Berardi E, Antonica G, Ferraioli G, Buonamico P, Godi L, et al. Comparison between the effect of l-propionyl carnitine, l-acetylcarnitine and nitroglycerin in chronic peripheral arterial disease: a haemodynamic double blind echo-Doppler study. Eur. Heart J. 1994;15(10):1348–1352
  17. Irat AM, Aktan F, Ozansoy G. Effects of l-carnitine treatment on oxidant/antioxidant state and vascular reactivity of streptozotocin-diabetic rat aorta. J. Pharm. Pharmacol. 2003;55(10):1389–1395
  18. Brevetti G, Angelini C, Rosa M, et al. Muscle carnitine deficiency in patients with severe peripheral vascular disease. Circulation. 1991;84(4):1490–1495
  19. Brevetti G, Angelini C, Rosa M, Carrozzo R, Perna S, Corsi M, et al. Effects of ischaemic stress on leukocyte activation processes in patients with chronic peripheral occlusive arterial disease: role of l-propionyl carnitine administration. Pharmacol. Res. 2001;44(4):305–309
  20. Brass EP, Hiatt WR. The role of carnitine and carnitine supplementation during exercise in man and in individuals with special needs. J. Am. Coll. Nutr. 1998;17(3):207–215
  21. Brevetti G, Chiariello M, Ferulano G, Policicchio A, Nevola E, Rossini A, et al. Increases in walking distance in patients with peripheral vascular disease treated with l-carnitine: a double-blind, cross-over study. Circulation. 1988;77(4):767–773
  22. Signorelli S, Di Pino L, Costa MP, et al. Efficacy of l-propionyl carnitine in the treatment of chronic critical limb ischemia. Clin. Drug Invest. 2001;21(8):555–561
  23. Barker GA, Green S, Askew CD, Green AA, Walker PJ. Effect of propionyl-l-carnitine on exercise performance in peripheral arterial disease. Med. Sci. Sports Exerc. 2001;33(9):1415–1422
  24. Creager MA. Medical management of peripheral arterial disease. Cardiol. Rev. 2001;9(4):238–245
  25. Poli G, Schaur RJ. 4-Hydroxynonenal in the pathomechanisms of oxidative stress. IUBMB Life. 2000;50(4/5):315–321
  26. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog. Lipid Res. 2003;42(4):318–343
  27. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem. 1982;126(1):131–138
  28. Nims RW, Cook JC, Krishna MC, Christodoulou D, Poore CM, Miles AM, et al. Methods Enzymol. 1996;268:93–105
  29. Hiatt WR. Treatment of disability in peripheral arterial disease: new drugs. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2004;4(3):227–231
  30. Bremer J. Carnitine—metabolism and functions. Physiol. Rev. 1983;63(4):1420–1480
  31. Genuth SM, Hoppel CL. Plasma and urine carnitine in diabetic ketosis. Diabetes. 1979;28(12):1083–1087
  32. Hoppel CL, Genuth SM. Carnitine metabolism in normal-weight and obese human subjects during fasting. Am. J. Physiol. 1980;238(5):E409–E415
  33. Hiatt WR, Nawaz D, Brass EP. Carnitine metabolism during exercise in patients with peripheral vascular disease. J. Appl. Physiol. 1987;62(6):2383–2387
  34. Harrison DG, Ohara Y. Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis: implications for impaired vasomotion. Am. J. Cardiol. 1995;75(6):75B–81B
  35. Askew CD, Green S, Hou XY, Walker PJ. Skeletal muscle mitochondrial ATP production rate and walking performance in peripheral arterial disease. Clin. Physiol. Funct. Imaging. 2002;22(3):226–232
  36. De Gaetano A, Mingrone G, Castagneto M, et al. Carnitine increases glucose disposal in humans. J. Am. Coll. Nutr. 1999;18(4):289–295
  37. Mingrone G, Greco AV, Capristo E, Benedetti G, Giancaterini A, De Gaetano A, et al. l-Carnitine improves glucose disposal in type 2 diabetic patients. J. Am. Coll. Nutr. 1999;18(1):77–82

PII: S0168-8227(05)00412-2

doi: 10.1016/j.diabres.2005.10.007

Diabetes Research and Clinical Practice
Volume 72, Issue 3 , Pages 231-237 , June 2006

Article Tools

* Image Usage & Resolution